XML 27 R17.htm IDEA: XBRL DOCUMENT ﻿
v2.3.0.11

Segment Information | 6 Months Ended | 12 Months Ended
--- | --- | ---
Jun. 30, 2011 | Dec. 31, 2010
Segment Information | ## Note 11 — Segment Information The Company’s financial information broken down by reportable segment was as follows (in thousands):
|  | Three Months Ended June 30, |  | Six Months Ended June 30,
|  | 2011 |  | 2010 |  | 2011 |  | 2010
Revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Pharmaceutical Manufacturing — China |  | $ | 16,151.2 |  |  | $ | 19,369.7 |  |  | $ | 34,292.9 |  |  | $ | 35,144.2 |
Cell Therapy — United States |  |  | 2,210.8 |  |  |  | 37.8 |  |  |  | 3,660.0 |  |  |  | 96.5 |
Regenerative Medicine — China |  |  | 98.7 |  |  |  | — |  |  |  | 148.9 |  |  |  | — |
|  | $ | 18,460.7 |  |  | $ | 19,407.5 |  |  | $ | 38,101.8 |  |  | $ | 35,240.7 |
Loss from operations |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Pharmaceutical Manufacturing — China |  | $ | 642.6 |  |  | $ | 3,559.0 |  |  | $ | 2,762.2 |  |  | $ | 6,749.7 |
Cell Therapy — United States |  |  | (2,937.2 | ) |  |  | (3,042.4 | ) |  |  | (6,977.7 | ) |  |  | (4,612.5 | )
Regenerative Medicine — China |  |  | (435.2 | ) |  |  | (423.4 | ) |  |  | (1,165.3 | ) |  |  | (736.9 | )
Corporate office |  |  | (7,288.7 | ) |  |  | (3,596.1 | ) |  |  | (12,629.4 | ) |  |  | (7,511.5 | )
|  | $ | (10,018.5 | ) |  | $ | (3,502.9 | ) |  | $ | (18,010.2 | ) |  | $ | (6,111.2 | )
Total assets |  | June 30, 2011 |  | December 31, 2010 |  |  |  |
Pharmaceutical Manufacturing — China |  | $ | 127,547.7 |  |  | $ | 125,133.7 |  |  |  |  |  |  |  |  |
Cell Therapy — United States |  |  | 34,810.9 |  |  |  | 1,241.2 |  |  |  |  |  |  |  |  |
Regenerative Medicine — China |  |  | 3,471.1 |  |  |  | 5,032.9 |  |  |  |  |  |  |  |  |
Corporate office |  |  | 4,502.7 |  |  |  | 11,616.9 |  |  |  |  |  |  |  |  |
|  | $ | 170,332.4 |  |  | $ | 143,024.7
| ## Note 11 — Segment Information The Company’s financial information broken down by reportable segment was as follows (in thousands):
|  | Years Ended December 31,
|  | 2010 |  | 2009 |  | 2008
Revenues |  |  |  |  |  |  |  |  |  |  |  |
Pharmaceutical Manufacturing — China |  | $ | 69,584.3 |  |  | $ | 11,386.7 |  |  | $ | — |
Cell Therapy — United States |  |  | 181.1 |  |  |  | 178.4 |  |  |  | 83.5 |
Regenerative Medicine — China |  |  | 55.9 |  |  |  | — |  |  |  | — |
|  | $ | 69,821.3 |  |  | $ | 11,565.1 |  |  | $ | 83.5 |
Income (loss) from operations |  |  |  |  |  |  |  |  |  |  |  |
Pharmaceutical Manufacturing — China |  | $ | 8,475.9 |  |  | $ | 487.3 |  |  | $ | — |
Cell Therapy — United States |  |  | (9,690.4 | ) |  |  | (5,875.2 | ) |  |  | (2,832.4 | )
Regenerative Medicine — China |  |  | (1,427.1 | ) |  |  | (1,753.5 | ) |  |  | — |
Corporate office |  |  | (16,236.7 | ) |  |  | (18,727.5 | ) |  |  | (6,401.1 | )
|  | $ | (18,878.3 | ) |  | $ | (25,868.9 | ) |  | $ | (9,233.5 | )
Total assets |  |  |  |  |  |  |  |  |  |  |  |
Pharmaceutical Manufacturing — China |  | $ | 125,133.7 |  |  | $ | 104,899.5 |  |  | $ | — |
Cell Therapy — United States |  |  | 1,241.2 |  |  |  | 2,033.0 |  |  |  | 1,361.5 |
Regenerative Medicine — China |  |  | 5,032.9 |  |  |  | 2,019.0 |  |  |  | — |
Corporate office |  |  | 11,616.9 |  |  |  | 2,124.8 |  |  |  | 462.8 |
|  | $ | 143,024.7 |  |  | $ | 111,076.3 |  |  | $ | 1,824.3

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 12 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8595-108599 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8538-108599 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 33 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8971-108599 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 34 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8981-108599 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 29 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8864-108599 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8380-108599 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 35 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8984-108599 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9038-108599 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8933-108599 Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 131 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 11: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599 Reference 12: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 26 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8844-108599 Reference 13: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9031-108599 Reference 14: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9054-108599 Reference 15: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8924-108599 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration